RETATRUTIDE - 46 Anuncios

Tuesday 29 July 2025

Cantidad : 10mg*10via - Precio : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Cantidad : 5mg*10vial - Precio : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday 26 July 2025

Cantidad : 5mg*10vial - Precio : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 60mg*10via - Precio : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 50mg*10via - Precio : USD 550

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 40mg*10via - Precio : USD 450

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 30mg*10via - Precio : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 20mg*10via - Precio : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 15mg*10via - Precio : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 10mg*10via - Precio : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Cantidad : 5mg*10vial - Precio : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 09 July 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 04 July 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 25 June 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 22 April 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 16 April 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...